文献速递泌尿生殖骨肌PET

转移性前列腺癌中的18F-NaF/223RaCl2诊疗一体化:治疗反应评估与结局预测

18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.
PubMed 文献 · Br J Radiol · 2018-04-16

本文综述18F-NaF PET闪烁显像与α粒子钙模拟剂223RaCl2构成的诊疗一体化模型在前列腺癌骨转移管理中的应用,重点总结18F-NaF及其他相关PET放射性示踪剂在223RaCl2治疗反应评估和预后判断中的效用。223RaCl2于2013年获监管批准后,相关证据不断积累。

要点

  • 18F-NaF PET与223RaCl2构成针对骨转移的诊疗一体化配对。
  • 18F-NaF PET可用于评估接受223RaCl2治疗的去势抵抗性前列腺癌患者的治疗反应。
  • 18F-NaF PET及其他相关PET示踪剂可用于预测接受223RaCl2治疗患者的结局。

核心结论

  • 18F-NaF/223RaCl2可作为前列腺癌管理中的诊疗一体化 companion,18F-NaF及其他相关PET放射性示踪剂在治疗反应和预后评估中具有效用。

研究设计与样本

  • 综述,聚焦18F-NaF/223RaCl2诊疗一体化在前列腺癌管理中的应用,重点为18F-NaF及其他相关PET放射性示踪剂在治疗反应与预后评估中的效用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Theranostics refers to companion agents with identical or similar structure targeted to a specific biological entity for imaging and treatment. Although the concept has a long history with radioiodine in thyroidology, but it has experienced remarkable recent renaissance in management of neuroendocrine tumors and prostate cancer. Bone scintigraphy based on osteoblastic reaction and targeted radionuclide therapy with the alpha-particle calcium-mimetic agent, 223RaCl2, also form a theranostic model for imaging and treatment of osseous metastatic disease. Since the regulatory approval of 223RaCl2 in 2013, there has been accumulating evidence on the potential use of 18F-NaF PET scintigraphy in the assessment of response and prediction of outcome in males with metastatic castrate-resistant prostate cancer who undergo 223RaCl2 therapy. We review the 18F-NaF/223RaCl2 as theranostic companion in the management of prostate cancer with emphasis on the utility of 18F-NaF and other relevant PET radiotracers in the therapy response and prognosis assessments.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Jadvar H, Colletti PM. 18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. Br J Radiol. 2018. PMID: 29630398. doi:10.1259/bjr.20170948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。